• Meropenem trihydrate in Resistance Research

  2026-08-16

  Build reproducible workflows for susceptibility testing, resistance phenotyping, and LC-MS/MS metabolomics with a broad-spectrum carbapenem antibiotic. Practical guidance connects meropenem exposure design with CPE biomarker discovery, while keeping formulation, stability, and translational limitations visible.

• Prochlorperazine in Melanoma Research Workflows

  2026-08-15

  Prochlorperazine combines dopamine D2 receptor antagonism with experimentally useful effects on melanoma viability, motility, MITF, and tyrosinase. This workflow-oriented guide shows how to build reproducible concentration-response, wound-healing, and protein-expression assays while avoiding solvent, formulation, and interpretation errors.

• Imatinib (STI571) for Reliable Kinase Assays

  2026-08-14

  A scenario-based guide to using Imatinib (STI571), SKU B2171, in cell viability, proliferation, cytotoxicity, and kinase-signaling workflows. It connects target potency, formulation, controls, protocol parameters, and CML-related interpretation to improve experimental consistency without overstating what a viability endpoint can prove.

• PDGF-BB: Murine Recombinant Protein for Vascular Assays

  2026-08-14

  Use murine recombinant PDGF-BB as a defined mitogenic comparator for smooth muscle and connective-tissue cell models, then layer it with hypoxia or metabolic stress to dissect vascular remodeling. This workflow connects receptor-driven proliferation with the lactate–ALDOB–DRP1 biology highlighted in pulmonary hypertension research.

• Silk Fibroin–Ce6 Films for Infected Wound Healing

  2026-08-13

  The reference study developed an aligned silk fibroin electrospun film conjugated with Chlorin e6 (Ce6) for light-activated treatment of Staphylococcus aureus-infected wounds. Its significance lies in combining directional cell guidance, reactive oxygen species generation, antibacterial photodynamic therapy, and later-stage macrophage modulation within one biomaterial platform.

• Oxaliplatin: From DNA Damage to Translation

  2026-08-13

  Oxaliplatin is more than a cytotoxic reagent: it is a mechanistic probe for DNA damage, apoptosis, treatment resistance, and biomarker-guided translation. This thought-leadership guide connects its platinum-DNA adduct activity with SMC2 and SMC4 findings in breast cancer, practical validation strategies, and more predictive cancer chemotherapy research.

• Ibotenic acid: Reliable Assay Design

  2026-08-12

  Learn how Ibotenic acid, SKU B6246, can support controlled glutamatergic challenge experiments while reducing variability from identity, solubility, and stock-handling errors. This scenario-based guide connects cell viability assay practice with circuit-level neuroscience evidence and practical vendor-selection criteria.

• CPI-613 Workflows for Tumor Metabolism

  2026-08-12

  Build reproducible CPI-613 experiments that connect mitochondrial enzyme inhibition with ATP loss, membrane-potential collapse, apoptosis, and tumor–macrophage signaling. The workflow combines practical dose-finding with a cholangiocarcinoma-focused strategy for testing PDHA1-linked metabolic and chemotherapy-resistance mechanisms.

• Gingerenone A Re-sensitizes RCC to Sunitinib

  2026-08-11

  This January 2026 study identifies gingerenone A as an LDHA-directed metabolic inhibitor that suppresses glycolysis and restores sunitinib activity in renal cell carcinoma models. Its combination of target-discovery analysis, metabolic rescue experiments, drug-synergy testing, and in vivo validation supports glycolysis as a practical strategy for addressing TKI resistance.

• Oleanolic Acid in Dual-Loaded Liposome Workflows

  2026-08-11

  Learn how to handle Oleanolic acid as a DMSO-soluble triterpenoid and incorporate it into dual-loaded liposome research. A validated nanoparticle exclusion chromatography workflow helps distinguish free compound from encapsulated cargo when lipophilic and hydrophilic drugs are analyzed together.

• Deracoxib Workflows for COX-2 Research

  2026-08-10

  Build reproducible Deracoxib workflows for COX-2 inhibition, canine pain and inflammation research, and tumor-cell assays. This guide connects assay design with solvent handling, combination-treatment logic, translational limits, and practical troubleshooting.

• Spermine Tetrahydrochloride: From Charge to Translation

  2026-08-09

  A translational perspective on how spermine tetrahydrochloride connects membrane stabilization, protein crystallization, and ionic polyphosphazene formulation while defining the evidence boundaries for neuroscience and therapeutic research.

• Ertugliflozin (PF-04971729) Assay Guide

  2026-08-08

  A scenario-based guide to using Ertugliflozin (PF-04971729), SKU A3715, in cell viability, proliferation, cytotoxicity, and SGLT2-mediated glucose transport workflows. It covers assay interpretation, solvent compatibility, protocol controls, clinical evidence boundaries, and practical supplier-selection criteria.

• FXYD5 Downregulation Reverses Cisplatin Resistance

  2026-08-07

  The reference study identifies FXYD5 as a functional contributor to cisplatin resistance in epithelial ovarian cancer models rather than merely a prognostic correlate. Using MTT-derived IC50 measurements alongside proliferation, motility, invasion, apoptosis, qRT-PCR, and immunoblotting assays, the authors show that FXYD5 silencing resensitizes resistant cells while suppressing drug-efflux and epithelial–mesenchymal transition-associated features.

• Latrunculin B: Guiding High-Precision Actin Disruption Studi

  2026-08-07

  Explore Latrunculin B as a potent actin cytoskeleton inhibitor, with a focus on mechanistic insight, precise protocol parameters, and critical data for assay design. This analysis uniquely connects molecular action with real-world limitations to empower advanced cytoskeletal research.

8642 records 8/577 page Previous Next First page 上5页 678910 下5页 Last page